<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">oCABERGOLINE</span><br/>(ka-ber'go-leen)<br/><span class="topboxtradename">Dostinex<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">ergot alkaloid</span><br/><b>Prototype: </b>Ergotamine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Cabergoline is a synthetic ergot derivative, long-acting dopamine receptor agonist with a high affinity for D<sub>2</sub> receptors.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Cabergoline inhibits both puerperal lactation and pathologic hyperprolactinemia.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of hyperprolactinemia (idiopathic or secondary to pituitary adenomas).</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of Parkinson's disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Uncontrolled hypertension and hypersensitivity to ergot derivatives; pregnancy (category B), pregnancy-induced hypertension,
         lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic function impairment. Safety and efficacy in pediatric patients are unknown.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hyperprolactinemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 0.25 mg 2 times/wk, may increase by 0.25 mg 2 times/wk to a max of 1 mg 2 times/wk<br/><br/><span class="indicationtitle">Parkinson's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 0.5 mg q.d., may increase up to 2.5 mg q.d. (max: 5 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on same days each week.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, fatigue, hot flashes. <span class="typehead">CV:</span> Postural hypotension. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, constipation,</span> abdominal pain, dyspepsia, vomiting, dry mouth, diarrhea, flatulence. <span class="typehead"> Endocrine:</span> Breast pain, dysmenorrhea. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache, dizziness,</span> paresthesia, somnolence, depression, nervousness. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Cabergoline should not be used concurrently with <span class="classification">phenothiazines</span>, <span class="classification">butyrophenones</span>, <span class="classification">thioxanthines</span>, and <b>metoclopramide</b> to avoid decreased therapeutic effects of both drugs. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract, undergoes first-pass metabolism. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Distribution:</span> 4042% protein bound. Crosses placenta, will interfere with ability to lactate. <span class="typehead">Metabolism:</span> Extensively metabolized. <span class="typehead">Elimination:</span> Approximately 22% excreted in urine, 60% in feces. <span class="typehead">Half-Life:</span> 6369 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor serum prolactin levels to assess response to each dosing level.</li>
<li>Monitor for hypotension, especially when given with other drugs known to lower BP.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Discontinue this drug once physician advises that serum prolactin level has been maintained for 6 mo.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>